静脉对乙酰氨基酚与安慰剂联合丙泊酚或右美托咪定对老年心脏手术后谵妄的影响:DEXACET随机临床试验
该随机、安慰剂对照、析因临床试验在美国单中心纳入120例60岁及以上行体外循环冠状动脉旁路移植术(CABG)或CABG联合瓣膜手术的患者,术后每6小时静脉对乙酰氨基酚或安慰剂共48小时,并联合右美托咪定或丙泊酚镇静(关胸开始,持续至多6小时)。主要终点为采用谵妄评估法(Confusion Assessment Method)判定的术后院内谵妄发生率。静脉对乙酰氨基酚组谵妄10% vs 安慰剂组28%(差值-18%,95%CI -32%至-5%,P=0.01;HR 2.8,95%CI 1.1-7.8),右美托咪定与丙泊酚组无显著差异(17% vs 21%,P=0.54)。对乙酰氨基酚还改善谵妄持续时间、ICU停留时间和突破性镇痛需求。作者认为需进一步研究比较静脉与口服对乙酰氨基酚及其他阿片节约型镇痛药对术后谵妄的影响。
要点
- 老年心脏手术后静脉对乙酰氨基酚每6小时共48小时,院内谵妄发生率10% vs 安慰剂28%(差值-18%,95%CI -32%至-5%,P=0.01;HR 2.8,95%CI 1.1-7.8)。
- 右美托咪定与丙泊酚相比谵妄发生率无显著差异(17% vs 21%,差值-4%,95%CI -18%至10%,P=0.54;HR 0.8,95%CI 0.4-1.9)。
- 对乙酰氨基酚较安慰剂缩短谵妄持续时间(中位1 vs 2天,差值-1,95%CI -2至0)、ICU停留时间(中位29.5 vs 46.7小时,差值-16.7,95%CI -20.3至-0.8)并减少突破性镇痛需求(中位322.5 vs 405.3 µg吗啡当量,差值-83,95%CI -154至-14)。
- 右美托咪定与丙泊酚仅突破性镇痛需求有显著差异(中位328.8 vs 397.5 µg,差值-69,95%CI -155至-4,P=0.04)。
- 低血压在安慰剂-右美托咪定组和対乙酰氨基酚-丙泊酚组各14例(46%和45%),在对乙酰氨基酚-右美托咪定组和安慰剂-丙泊酚组各7例(24%和23%)。
适用人群与场景
- 年龄60岁及以上、接受体外循环冠状动脉旁路移植术(CABG)或CABG联合瓣膜手术的患者。
- 美国单中心,入组时间2015年9月至2018年4月,随访至2019年4月。
处置流程与药物剂量
- 术后镇痛:静脉对乙酰氨基酚或安慰剂每6小时一次,共48小时。
- 术后镇静:关胸时开始静脉右美托咪定或丙泊酚,持续至多6小时。
- 四组分配:对乙酰氨基酚+右美托咪定(n=29)、安慰剂+右美托咪定(n=30)、对乙酰氨基酚+丙泊酚(n=31)、安慰剂+丙泊酚(n=30)。
研究设计与关键结果
- 随机、安慰剂对照、析因临床试验,121例随机(中位年龄69岁;女性19例[15.8%]),120例完成试验。
- 主要终点:静脉对乙酰氨基酚组谵妄发生率10% vs 安慰剂组28%(差值-18%,95%CI -32%至-5%,P=0.01;HR 2.8,95%CI 1.1-7.8)。
- 右美托咪定 vs 丙泊酚谵妄发生率17% vs 21%(差值-4%,95%CI -18%至10%,P=0.54;HR 0.8,95%CI 0.4-1.9)。
- 对乙酰氨基酚 vs 安慰剂预设次要终点:谵妄持续时间中位1 vs 2天(差值-1,95%CI -2至0);ICU停留时间中位29.5 vs 46.7小时(差值-16.7,95%CI -20.3至-0.8);突破性镇痛需求中位322.5 vs 405.3 µg吗啡当量(差值-83,95%CI -154至-14)。
- 右美托咪定 vs 丙泊酚仅突破性镇痛需求有显著差异(中位328.8 vs 397.5 µg,差值-69,95%CI -155至-4,P=0.04)。
- 低血压:安慰剂-右美托咪定组14例(46%)、对乙酰氨基酚-丙泊酚组14例(45%)、对乙酰氨基酚-右美托咪定组7例(24%)、安慰剂-丙泊酚组7例(23%)。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照、析因临床试验。
- 局限:作者在结论中提出需进一步研究,包括比较静脉与口服对乙酰氨基酚及其他阿片节约型镇痛药对术后谵妄发生率的影响。
对床旁实践的改变
- 作者认为,老年心脏手术患者术后每6小时静脉对乙酰氨基酚联合静脉丙泊酚或右美托咪定,较安慰剂降低院内谵妄发生率。
- 作者认为,需进一步研究比较静脉与口服对乙酰氨基酚及其他阿片节约型镇痛药对术后谵妄的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Postoperative delirium is common following cardiac surgery and may be affected by choice of analgesic and sedative.
OBJECTIVE: To evaluate the effect of postoperative intravenous (IV) acetaminophen (paracetamol) vs placebo combined with IV propofol vs dexmedetomidine on postoperative delirium among older patients undergoing cardiac surgery.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, placebo-controlled, factorial clinical trial among 120 patients aged 60 years or older undergoing on-pump coronary artery bypass graft (CABG) surgery or combined CABG/valve surgeries at a US center. Enrollment was September 2015 to April 2018, with follow-up ending in April 2019.
INTERVENTIONS: Patients were randomized to 1 of 4 groups receiving postoperative analgesia with IV acetaminophen or placebo every 6 hours for 48 hours and postoperative sedation with dexmedetomidine or propofol starting at chest closure and continued for up to 6 hours (acetaminophen and dexmedetomidine: n = 29; placebo and dexmedetomidine: n = 30; acetaminophen and propofol: n = 31; placebo and propofol: n = 30).
MAIN OUTCOMES AND MEASURES: The primary outcome was incidence of postoperative in-hospital delirium by the Confusion Assessment Method. Secondary outcomes included delirium duration, cognitive decline, breakthrough analgesia within the first 48 hours, and ICU and hospital length of stay.
RESULTS: Among 121 patients randomized (median age, 69 years; 19 women [15.8%]), 120 completed the trial. Patients treated with IV acetaminophen had a significant reduction in delirium (10% vs 28% placebo; difference, -18% [95% CI, -32% to -5%]; P = .01; HR, 2.8 [95% CI, 1.1-7.8]). Patients receiving dexmedetomidine vs propofol had no significant difference in delirium (17% vs 21%; difference, -4% [95% CI, -18% to 10%]; P = .54; HR, 0.8 [95% CI, 0.4-1.9]). There were significant differences favoring acetaminophen vs placebo for 3 prespecified secondary outcomes: delirium duration (median, 1 vs 2 days; difference, -1 [95% CI, -2 to 0]), ICU length of stay (median, 29.5 vs 46.7 hours; difference, -16.7 [95% CI, -20.3 to -0.8]), and breakthrough analgesia (median, 322.5 vs 405.3 µg morphine equivalents; difference, -83 [95% CI, -154 to -14]). For dexmedetomidine vs propofol, only breakthrough analgesia was significantly different (median, 328.8 vs 397.5 µg; difference, -69 [95% CI, -155 to -4]; P = .04). Fourteen patients in both the placebo-dexmedetomidine and acetaminophen-propofol groups (46% and 45%) and 7 in the acetaminophen-dexmedetomidine and placebo-propofol groups (24% and 23%) had hypotension.
CONCLUSIONS AND RELEVANCE: Among older patients undergoing cardiac surgery, postoperative scheduled IV acetaminophen, combined with IV propofol or dexmedetomidine, reduced in-hospital delirium vs placebo. Additional research, including comparison of IV vs oral acetaminophen and other potentially opioid-sparing analgesics, on the incidence of postoperative delirium is warranted.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02546765.
参考来源
- Subramaniam B, Shankar P, Shaefi S, et al. Effect of Intravenous Acetaminophen vs Placebo Combined With Propofol or Dexmedetomidine on Postoperative Delirium Among Older Patients Following Cardiac Surgery: The DEXACET Randomized Clinical Trial. JAMA. 2019. PMID: 30778597. doi:10.1001/jama.2019.0234
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。